目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ASSESSMENT APPROACH

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 REGULATORY LANDSCAPE
5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.2 REGULATORY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
5.6 TECHNOLOGY MAP
5.7 REIMBERSEMENT SCENARIO
5.8 TRADE DATA
5.9 PATENT DATA
5.10 PORTER’S FIVE FORCE ANALYSIS
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS BY PRODUCT
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
5.12 CASE STUDY
5.13 KEY CONFERENCES AND EVENTS IN 2023-24
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS

6 CARDIAC MARKER TESTING MARKET, BY PRODUCT (USD MILLION; 2021—2028)*
6.1 REAGENTS & KITS
6.2 INSTRUMENTS
6.2.1 CHEMILUMINESCENCE
6.2.2 IMMUNOFLUORESCENCE
6.2.3 ELISA
6.2.4 IMMUNOCHROMATOGRAPHY

7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE (USD MILLION; 2021—2028)*
7.1 TROPONIN I AND T
7.2 CREATINE KINASE-MB (CK-MB)
7.3 BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP)
7.4 MYOGLOBIN
7.5 HIGH-SENSITIVITY C-REACTIVE PROTEIN (HSCRP)
7.6 OTHER CARDIAC BIOMARKERS (ISCHEMIA -MODIFIED ALBUMIN (IMA), H-FABP, MYELOPEROXIDASE, OTHERS)

8 CARDIAC MARKER TESTING MARKET, BY DISEASE (USD MILLION; 2021—2028)*
8.1 MYOCARDIAL INFARCTION
8.2 CONGESTIVE HEART FAILURE
8.3 ACUTE CORONARY SYNDROME
8.4 ATHEROSCLEROSIS
8.5 ISCHEMIA

9 CARDIAC MARKER TESTING MARKET, BY END-USER (USD MILLION; 2021—2028)*
9.1 LABORATORY TESTING FACILITIES
9.1.1 HOSPITAL LABORATORIES
9.1.2 REFERENCE LABORATORIES
9.1.3 CONTRACT TESTING LABORATORIES
9.2 ACADEMIC INSTITUTES
9.2 POINT-OF-CARE TESTING FACILITIES

10 CARDIAC MARKER TESTING MARKET, BY REGION (USD MILLION; 2021—2028)*
10.1 NORTH AMERICA
10.1.1 RECESSION IMPACT
10.1.2 US
10.1.3 CANADA
10.2 EUROPE
10.2.1 RECESSION IMPACT
10.2.2 GERMANY
10.2.3 UK
10.2.4 FRANCE
10.2.5 ITALY
10.2.6 SPAIN
10.2.7 REST OF EUROPE
10.3 ASIA-PACIFIC
10.3.1 RECESSION IMPACT
10.3.2 JAPAN
10.3.3 CHINA
10.3.4 INDIA
10.3.5 SOUTH KOREA
10.3.6 AUSTRALIA
10.3.7 REST OF ASIA-PACIFIC
10.4 LATIN AMERICA
10.4.1 RECESSION IMPACT
10.4.2 BRAZIL
10.4.3 MEXICO
10.4.4 REST OF LATIN AMERICA
10.5 MIDDLE EAST AND AFRICA
10.5.1 RECESSION IMPACT

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE ANALYSIS OF KEY PLAYERS (2022)
11.4 MARKET SHARE ANALYSIS FOR TOP 5 GLOBAL PLAYERS (IN TERMS OF %REVENUE, IN 2022)
11.5 COMPANY EVALUATION MATRIX
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT
11.6 SME/START-UP EVALUATION MATRIX
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING
11.7 COMPETITIVE SITUATION AND TRENDS (2021-2023)
11.7.1 PRODUCT LAUNCHES
11.7.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
11.7.3 MERGERS & ACQUISITIONS
11.7.4 EXPANSIONS

12 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
12.1 KEY COMPANIES
12.1.1 F. HOFFMANN-LA ROCHE AG
12.1.2 ABBOTT LABORATORIES
12.1.3 SIEMENS HEALTHINEERS AG
12.1.4 DANAHER CORPORATION
12.1.5 BIOMÉRIEUX SA
12.1.6 BIO-RAD LABORATORIES, INC.
12.1.7 THERMO FISHER SCIENTIFIC INC.
12.1.8 PERKINELMER, INC.
12.1.9 TOSOH CORPORATION
12.1.10 DIASORIN
12.1.11 BECTON, DICKINSON AND COMPANY (BD)
12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION)
12.1.13 QUIDEL CORPORATION
12.1.14 RANDOX LABORATORIES
12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD.
12.1.16 BODITECH MED INC.
12.1.17 TULIP (P) DIAGNOSTICS LTD
12.1.18 BTNX INC.
12.1.19 RESPONSE BIOMEDICAL
12.1.20 ALFA SCIENTIFIC DESIGNS, INC.
12.2 OTHER PLAYERS
12.2.1 CTK BIOTECH, INC.
12.2.2 CREATIVE DIAGNOSTICS
12.2.3 LIFESIGN LLC.
12.2.4 CARDIOGENICS HOLDINGS INC
12.2.5 ATLAS MEDICAL GMBH

13 APPENDIX